The following drugs are in various stages of clinical studies and trials.
In the Pipeline
In the Pipeline
- Myogen has begun patient enrollment in Phase III clinical trials of ambrisentan for the treatment of pulmonary arterial hypertension.
- Genome Sciences has begun dosing patients in a Phase II clinical trial of human monoclonal antibody to B-lymphocyte stimulator, BlyS (LymphoStat-B), for the treatment of rheumatoid arthritis.
- Favrille has completed enrollment for its current Phase II clinical trial (FavId-04) with the company’s lead investigational agent, FavId. This agent is under clinical development for the treatment of follicular B-cell lymphomas following cytoreductive therapy with Rituxan.
- Cytheris has announced the entry of its first recombinant human Interleukin-7 protein in a Phase I clinical study. This cytokine targets the immune reconstitution of immunocompromised patients, including those undergoing cancer treatment, affected by AIDS, or recovering from a bone marrow transplant.
- Coley Pharmaceutical Group has initiated a Phase I clinical study of CPG 10101 (Actilon), a novel synthetic TLR9 agonist, targeted for patients with chronic hepatitis C infection.
- Peninsula Pharmaceuticals has announced that patient enrollment has begun in a Phase I trial of an inhaled formulation of its lead product candidate, doripenem, a broad-spectrum carbapenem antibiotic.
- Epimmune has completed patient enrollment in the Phase I/II therapeutic HIV vaccine trial of its EP HIV-1090 vaccine candidate.
- Progen Industries Limited has begun a new Phase II clinical study of its lead anticancer compound, PI-88.
- Pharmacyclics has initiated a Phase I clinical trial evaluating the safety and efficacy of its investigational drug motexafin gadolinium (Xcytrin) in combination with temozolomide (Temodar) for the treatment of patients with relapsed malignant gliomas.
- Allos Therapeutics has initiated a Phase I clinical trial of efaproxiral (RSR13) and supplemental oxygen with concurrent chemoradiation therapy in patients with locally advanced, unresectable (Stage IIIA/Stage IIIB) non-small cell lung cancer.
- Genencor International is beginning Phase I safety and immunogenicity testing for its DNA-based therapeutic vaccine to treat hepatitis B.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.